CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

CRISPR Therapeutics has developed SyNTase editing, a proprietary, next-generation, site-specific gene correction platform.

This makes the organs virus-free and less likely to trigger an immune response, improving their safety and durability.

A team led by scientists at Harvard Medical School, Massachusetts General Hospital, and the Broad Institute of MIT and ...

CRISPR Therapeutics (CRSP) just announced that its SyNTase gene editing technology will be featured in an oral presentation at the ESGCT 2025 Congress. This marks the first major public unveiling of ...

Gene-edited pancreatic cells have been transplanted into a patient with type 1 diabetes for the first time. They produced insulin for months without the patient needing to take immunosuppressants.

Stanford researchers and their collaborators have revealed a new device that could change the way scientists conduct ...

Algen Biotechnologies said on Monday it had agreed to grant AstraZeneca a license to develop therapies the U.S.-based biotech ...

Turning genes on and off is like flipping a light switch, controlling whether genes in a cell are active. When a gene is ...

The company is gene editing crops to make our food supply more resilient to climate change.

VedaBio, a pioneering biotechnology company transforming molecular detection, today announced a non-exclusive license agreement with Mammoth Biosciences, Inc. for the use of select CRISPR-based ...